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Abstract: In this study, we investigated the differential actions of a dominant-negative survivin 
mutant (SurR9-C84A) against cancerous SK-N-SH neuroblastoma cell lines and differentiated 
SK-N-SH neurons. In both the cases, the mutant protein displayed dual actions, where its effects 
were cytotoxic toward cancerous cells and proliferative toward the differentiated neurons. 
This can be explained by the fact that tumorous (undifferentiated SK-N-SH) cells have a high 
endogenous survivin pool and upon treatment with mutant SuR9-C84A causes forceful survivin 
expression. These events significantly lowered the microtubule dynamics and stability, eventu-
ally leading to apoptosis. In the case of differentiated SK-N-SH neurons that express negligible 
levels of wild-type survivin, the mutant indistinguishably behaved in a wild-type fashion. 
It also favored cell-cycle progression, forming the chromosome-passenger complex, and sta-
bilized the microtubule-organizing center. Therefore, mutant SurR9-C84A represents a novel 
therapeutic with its dual actions (cytotoxic toward tumor cells and protective and proliferative 
toward neuronal cells), and hence finds potential applications against a variety of neurological 
disorders. In this study, we also developed a novel poly(lactic-co-glycolic acid) nanoparticulate 
formulation to surmount the hurdles associated with the delivery of SurR9-C84A, thus enhanc-
ing its effective therapeutic outcome.
Keywords: survivin mutant, neurological disorders, protein therapeutics, inhibitor of apoptosis 
protein family, poly(lactic-co-glycolic acid)
Introduction
Neurotherapeutics has always been a rich area of research, considering the restricted 
potential of neuronal cells for proliferation and their inability to renew. Therefore, 
developing the strategies of neuronal proliferation and neuron protection are the prime 
ways of achieving effective therapeutics for neurological disorders.1–3 Several studies 
have aimed to treat neurological disorders, including cancers targeting the family of 
IAP proteins. Among these, the role of survivin in premature brain development has 
been very well documented.4–7 Supporting cell division, it plays an intriguing role in 
forming the chromosome-passenger complex (CPC), consisting of survivin, borealin, 
INCENP, and aurora B kinase. Survivin and borealin dimerize translocating the CPC 
to the central spindle. This event improves the stability of the microtubules facilitat-
ing the proper chromosome alignment onto the spindle fibers.8,9 It also acts against 
apoptosis, complexing with the HBXIP protein and its cofactor XIAP. This complex 
interacts with procaspase-9, avoiding the recruitment of APAF-1, and thereby prevents 
apoptosis.10 On the other hand, survivin significantly lowers microtubule dynamics and 
stability, eventually leading to apoptosis upon forceful expression.11 Considering the 
potential of survivin, we synthesized a mutant variety of it that carries an R9 peptide 
(polymeric arginine carrier) termed dominant-negative survivin (SurR9-C84A); the 
R9 peptide facilitates rapid uptake into the cells.12 SurR9-C84A belongs to the family 
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of IAPs, and tends to act by dual mechanisms against cancer-
ous and normal neuronal cells.
Cancer cells overexpress wild-type survivin, and when 
treated, SurR9-C84A displaces wild-type survivin, leading to 
increased levels of free Caspase 3 (Cas-3) and thereby induc-
ing cell death.13 In contrast, SurR9-C84A tends to promote 
proliferation, enhancing the CPC organization in neurons 
that have lower endogenous survivin expression.
These results were substantiated with our own data, 
where SurR9-C84A showed apoptotic effects toward pros-
tate cancer cells and proliferating effects toward retinoic 
acid-differentiated SK-N-SH neurons.12,14 The former effect 
of the mutant protein would be highly beneficial in the 
death-inducing events of degeneration and inflammation 
predominantly seen in Alzheimer’s disease and multiple 
sclerosis.15 On the other hand, protein and peptide therapy 
always suffer from the serious limitations of their half-life, 
physical and chemical instability, inefficient oral delivery, 
enzymatic degradation in the gastrointestinal tract, and poor 
permeation through biological barriers.16 Therefore, we 
tried to develop a novel nanoparticulate formulation for the 
delivery of SurR9-C84A and surmount the hurdles associated 
with protein delivery. Polymeric NPs made of poly(lactic-
co-glycolic acid) (PLGA) have gained extreme popularity in 
formulating several drugs, as they are biodegradable and also 
approved by the US Food and Drug Administration for human 
use.17 PLGA is available in different varieties, of which 
PLGA with a copolymer ratio of 50:50 lactide:glycolide 
was used for this study. This study is the first report on 
the encapsulation of SurR9-C84A in PLGA NPs using the 
modified double-emulsion technique. Polyvinyl alcohol 
(PVA; 1%) proved to be an effective emulsifier, yielding 
NPs with desirable size range and smooth spherical surface 
morphology. All the process parameters were optimized to 
achieve enhanced encapsulation and drug loading.
The integrity and intactness of the protein inside the 
polymer matrix were studied using Fourier-transform infra-
red spectroscopy (FTIR), sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE), and differential 
scanning calorimetry (DSC) techniques. The efficacy of 
the protein-loaded NPs was studied in the undifferentiated 
and differentiated (retinoic induced) human neuroblastoma 
(SK-N-SH) cell lines.
Materials and methods
The polymer poly(D,L-lactide-co-glycolide) Resomer® 
RG 503 H (PLGA 50:50, inherent viscosity 0.32–0.44 dL/g, 
molecular weight 24,000–38,000), and PVA (molecu-
lar weight 13,000–23,000, 87%–89% hydrolyzed) were 
procured from Sigma-Aldrich (St Louis, MO, USA). All other 
solvents and chemicals used in the study were of analytical 
grade. SK-N-SH neuroblastoma cell lines were obtained 
from the American Type Culture Collection (Manassas, VA, 
USA), and were grown as a monolayer in Eagle’s Minimum 
Essential Medium supplemented with 10% fetal bovine 
serum and 1% penicillin and streptomycin at 37°C in a 
saturated humid atmosphere with 5% CO
2
.
construction of mutant variety  
of survivin and its purification
Mutant dominant-negative survivin (SurR9-C84A) was 
constructed as described previously,18 where cysteine was 
replaced with alanine at 84th position in the zinc-coordination 
site. Also, the protein was endowed with enhanced cellular 
permeability, as the amino terminus of the protein was modi-
fied with nine arginine (R9) residues, hence the name SurR9-
C84A. The Escherichia coli BL21 strain was transfected with 
the SurR9-C84A-bearing plasmid, and protein expression 
was induced by incubating the E. coli bacteria in Luria–
Bertani broth media containing 0.01% weight/volume (w/v) 
ampicillin at 37°C. The incubation was terminated once the 
optical density of the broth medium reached 0.7 at 620 nm.
Then, protein expression was induced with 0.7 mM 
isopropylthiogalactoside by incubation for 3 hours. After 
this period, the bacterial cells were collected by centrifu-
gation at 4,500 rpm for 45 minutes at 4°C. The protein 
was collected by lysing the cell walls of the bacteria after 
treatment with a freshly prepared lysis buffer composed of 
(Milli-Q® [EMD Millipore, Billerica, MA, USA], 150 mM 
NaCl, 20% SDS, 50 mM Tris, lysozyme 0.1 mg/mL, 1% 
Triton™ X-100 [Sigma-Aldrich], and a protease inhibitor), 
followed by sonication at a 40-second pulse and 70 ampli-
tude for 7 minutes. The crude protein was collected after 
centrifugation, and then purified using the glutathione aga-
rose column. Purification of the protein was based on the 
principle of affinity chromatography, where the glutathione 
S-transferase-tagged protein bound to the column was eluted 
by running an elution buffer composed of 10 mM glutathione 
in 50 mM Tris-HCI, pH 7.5. The pure protein collected was 
frozen at -80°C for further experiments (Figure 1A).
Preparation of surr9-c84a-loaded 
Plga nanoparticles
The NPs were prepared following the principle of the modi-
fied double-emulsion technique followed by evaporation. 
The polymer (1% w/v) was dissolved in ethyl acetate, and 
two equal halves of it were taken in separate tubes. Protein 
(10 mg/mL) was prepared in 1% PVA and equally mixed 
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Figure 1A–H Physicochemical characterization of surr9-c84a loaded Plga NPs.
Notes: (A) sodium dodecyl sulfate gel and (B) Western blot for SurR9-C84A purified using the glutathione agarose column. A concentration of 40 µg/ml of the protein 
was loaded in each well and run through 12.5% gel, and later transferred onto a polyvinylidene difluoride membrane for SurR9-C84A detection. (C) scanning electron 
microscopy images of the void and (D) surr9-c84a-loaded Plga NPs. (E) In vitro release of surr9-c84a from the Plga NPs at ph 2 and 7.4, representing the acidic and 
neutral ph ranges that the NPs would encounter. The protein release reached saturation in 3 days at both ph ranges. (F) Differential scanning calorimetry curve for the 
void and surr9-c84a-loaded Plga NPs. a temperature range of 0°c–250°C was used with a heat-flow increment of 10°c/minute. an endothermic peak was observed at 
52°c, with no detectable changes comparatively between the void and protein-loaded NPs, inferring the amorphous nature of the protein upon encapsulation in the NPs. 
(G) Fourier-transform infrared spectra for the void and protein-loaded NPs. The peaks observed in the range of 1,650 cm–1 and 1,540 cm–1 corresponded to the amide I and 
II bands, respectively, inferring protein integrity and encapsulation. (H) The marker, void, and surr9-c84a-loaded NPs were run through a 12.5% gel at 200 V. a protein 
concentration of 40 µg/ml was loaded for the detection of surr9-c84a in the NPs. Presence of a 16 kDa band indicated both the successful encapsulation of the protein 
and its structural integrity.
Abbreviations: Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles; gsT, glutathione S-transferase.
with the polymer solution prepared, followed by sonica-
tion for 30 seconds, yielding the primary w/o emulsion. 
Then, the final volume was made to 15 mL with 1% PVA 
in each of the tubes, followed by sonication to yield the 
final water/oil/water (w/o/w) emulsion. The final emulsion 
was then stirred overnight at 800 rpm at 4°C to remove the 
organic solvent. The  protein-loaded NPs were collected 
after washing with distilled water followed by centrifugation 
at 4,500 rpm for 1 hour. Washing was done three times to 
ensure the collected NPs were pure, and they were immedi-
ately freeze-dried for 48 hours and stored at 4°C for further 
experiments.
Blank NPs were prepared following the same protocol, 
except the protein was replaced with Milli-Q water. The 
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fluorescence-labeled NPs were prepared using 4% rhodamine 
(R6G; Sigma-Aldrich). The R6G was added to the 1% w/v 
polymer solution prepared initially, and the rest of the pro-
cedure was the same as described earlier.19
characterization of nanoparticles
Particle size and surface morphology
Size analysis was performed by dynamic light scattering using 
a Malvern Zetasizer (Malvern Instruments, Malvern, UK). 
In brief, 1 mg of the freeze-dried NPs was dispersed in 1 mL 
of Milli-Q water and measurements were read at a scattering 
angle of 90° maintained at 25°C. Nanosphere morphology 
was ascertained by scanning electron microscopy (SEM) 
(Supra 55VP; Carl Zeiss Meditec, Jena, Germany), wherein 
the NPs suspended in water were subjected to sonication and 
mounted on the carbon tape followed by air-drying. Then, 
the stubs were gold-coated and left in the vacuum chamber 
overnight prior to SEM imaging at an accelerated voltage 
of 10 kV and a working distance of 12 and 9.9 mm.
Encapsulation efficiency and percentage loading
The prepared NPs were centrifuged at 4,500 rpm 
for 45  minutes at 4°C, and the supernatant was collected. 
Protein content in the supernatant was estimated using 
a Bradford protein-assay kit (Thermo Fisher Scientific, 
Scoresby, Victoria, Australia), and absorbance was measured 
at 620 nm. The amount of protein present was obtained from 
the concentration versus absorbance calibration curves of the 
known standards. Encapsulation efficiency and percentage 
loading were calculated using the following equations:
 Initial weight of  protein taken –
amount of  the protein left
Encapsulation in the supernatants
 efficiency Amount of  protein take
0
n
10×=
 eight of  the proteinW
Percentage loaded nanoparticles 100loading  Weight of  protein and polymer 
used for NP preparation
= ×
Polymer–protein interaction
To evaluate the possible polymer–protein interactions, DSC 
study was conducted for void and protein-loaded NPs. The 
corresponding DSC curves were obtained on a scanning 
calorimeter embedded with the thermal analysis-data sys-
tem. In brief, void and protein-loaded NPs were measured 
(4 mg) and sealed in aluminum pans. A blank aluminum 
pan was used as a reference, and the samples were scanned 
at a temperature ranging from -20°C to 250°C with a 
heat-flow increment of 10°C/minute and nitrogen purging 
at 20 mL/minute.
release kinetics
The in vitro kinetics of the SurR9-C84A-loaded PLGA NPs 
was evaluated in 10 mM phosphate-buffered saline (PBS) 
at 7.4 pH and an acidic pH 2, mimicking the in vivo conditions 
that NPs might encounter. A predetermined amount of the 
freeze-dried NPs was suspended in the PBS buffer, incubated 
at 37°C, and subjected to a constant rotation at 70 rpm. At regu-
lar intervals (0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 96 hours), 
aliquots were collected and the protein concentration was 
estimated using a spectrophotometer at 620 nm.
Fourier-transform infrared spectroscopy
A predetermined quantity of micronized infrared-grade KBr 
(400 mg) was mixed separately with the void and SurR9-C84A-
loaded NPs (1 mg dry weight) to prepare the pellets using a 
manually operated tablet press. A pressure of 5.5 metric tons 
for 5 minutes was applied, and the pellets were scanned 16 times 
over the mid-IR region (4,000–400 cm-1 wave-number range). 
Background spectra were subtracted from the samples, and the 
spectral data values were graphically represented using Excel 
(Microsoft, Redmond, WA, USA).
sDs-Page for protein integrity
The integrity of the protein encapsulated within the NPs was 
assessed by SDS-PAGE. The freeze-dried NPs were stored 
at 4°C for 1 week and run through the 12.5% SDS gel under 
reducing conditions (β-mercaptoethanol) including the void 
NPs as control. The gel was run in Tris/glycine/SDS buffer 
at a constant 100 V for 50 minutes using the Mini-Protean® 
electrophoresis system (Bio-Rad Laboratories Inc., Hercules, 
CA, USA). Coomassie blue (0.1%) was used as the gel stain 
for 30 minutes, followed by destaining with a high-destain solu-
tion (70% Milli-Q water, 20% methanol, and 10% acetic acid) 
and later the gel was visualized using the Gel Doc™ imaging 
system (Bio-Rad Laboratories Inc.).
In vitro nanoparticle-uptake studies
For the in vitro NP-uptake study, both differentiated and 
undifferentiated SK-N-SH cells were grown in Falcon™ 
eight-well culture slides (BD Biosciences, San Jose, CA, 
USA) at a density of 2×104 cells/well and incubated with 
rhodamine-labeled NPs at time points of 30 minutes and 1, 2, 
and 4 hours. After the specified time, the media were removed 
and cells washed thrice with 1× PBS to remove the free NPs 
that were neither taken up nor adhered to the cells.
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Cells were immediately fixed with 4% paraformaldehyde 
for 15 minutes, followed by washing and mounted with 
a coverslip using a Fluoroshield™ with 4′,6-diamidino-
2-phenylindole (DAPI; Sigma-Aldrich). Cellular uptake 
was determined using an SP5 confocal microscope (Leica 
Microsystems, Wetzlar, Germany), and all the images were 
taken at 40× magnification. The percentage internalization 
of NPs are expressed as means ± standard deviation obtained 
by counting cells in five or more different fields.
NP-uptake mechanism
To determine the precise NP-uptake mechanism, differentiated 
SK-N-SH cells were seeded at 2×104 cells per well in a 96-well 
plate. Then, they were pretreated with the endocytic inhibitors 
chlorpromazine (10 µg/mL, clathrin-mediated endocytosis), 
indomethacin (10 µg/mL, caveolae-mediated endocytosis), 
sodium azide (2 µg/mL), and colchicine (5 µg/mL, pinocy-
tosis) for 1 hour, followed by rhodamine-labeled NP incuba-
tions for 4 hours at 1 mg/mL concentration. After treatment, 
cells were washed with PBS to remove free NPs, and then 
the cells were lysed with 1% Triton X-100 in 0.2 M NaOH. 
The resulting fluorescence was measured at 530 excitation 
and 630 emission, and the corresponding weight of the NPs 
was calculated from the standard graph plotted for rhodamine-
labeled NPs. Flow-cytometry analysis was also performed, 
where SK-N-SH cells were plated in six-well plates and 
were treated with endocytic inhibitors as described above. 
After treatment, cells were washed with 1× PBS, detached 
gently by pipetting, and underwent flow-cytometry analysis.
retinoic acid-induced differentiation  
in sK-N-sh cells
Undifferentiated SK-N-SH cells are generated from bone 
marrow metastasis, and are subdivided into neuroblast (N) 
cells, substrate adherent nonneuronal (S) cells, and interme-
diate (I) cells.
N-type cells exhibit short neuronal processes, while the 
S-type cells are rather flat and strongly bound to the sub-
strate. The T-type cells display intermediate properties of 
both N and S cells with or without neuronal processes and 
substrate adherence. In order to induce differentiation in 
neuroblastoma cells, 20 µM retinoic acid (Sigma-Aldrich) 
was added to the culture media, with periodic replacement 
of the conditioned media every 2 days.20
Wild-type survivin expression in differentiated  
and undifferentiated sK-N-sh cells
In order to determine the differential expression of wild-type 
survivin, both differentiated and undifferentiated SK-N-SH 
cells were plated in eight-well culture slides at 2×104 per 
well and underwent immunofluorescence detection. Cells 
were permeabilized with 0.1% Triton X-100 in PBS, 
followed by blocking with 2% rabbit serum. Then, undif-
ferentiated and differentiated cells were incubated with a 
mouse monoclonal antisurvivin (Santa Cruz Biotechnology, 
Dallas, TX, USA) 1:100 dilution for 1 hour, followed by 
fluorescein isothiocyanate (FITC)-labeled rabbit antimouse 
(1:100; Sigma-Aldrich). The cell nucleus was stained with 
propidium iodide (PI; 1:500; Sigma-Aldrich) for 30 minutes 
and mounted with mounting media. Further imaging was 
carried out using the Leica SP5 confocal microscope at 40× 
magnification.
cytotoxicity in undifferentiated  
sK-N-sh cells
live and dead cell assay
Undifferentiated SK-N-SH cells were plated in a 96-well 
plate at a density of 2×104 cells/well, followed by treat-
ment with void and SurR9-C84A-loaded NPs (25, 50, 100, 
and 200 µg of protein/mL concentration) for 24 hours. 
Untreated controls, including positive controls (treated 
with 20% fetal bovine serum [FBS]) and negative controls 
(treated with 1% Triton X-100), were included in the study 
for the calculation of percentage live and dead cells. The 
entire procedure was followed as per the manufacturer’s 
protocol (Live/Dead® viability/cytotoxicity kit; Thermo 
Fisher Scientific, Waltham, MA, USA). The live/dead 
cell readings posttreatment were recorded using a fluores-
cence microplate reader at 530 nm excitation and 645 nm 
emission.
cell-proliferation study
In order to evaluate the proliferative potential of SurR9-C84A 
on undifferentiated SK-N-SH cells, a CyQuant® (Thermo 
Fisher Scientific) assay was performed. SK-N-SH cells were 
plated in the 96-well culture plate at a density of 2×104 cells/well 
and incubated with NP treatments corresponding to protein 
concentrations of 25, 50, 100, and 200 µg/mL for 24 hours. 
An untreated control, void NP-treated (control for protein-
loaded NPs), and 20% FBS-treated (negative control) cells 
were also included in the study. After treatment, the cells 
were washed and frozen overnight at -80°C, followed 
by the addition of 200 µL/well of CyQuant dye reaction 
mixture prepared as per the manufacturer’s protocol. Read-
ings were taken at 480 nm excitation and 520 nm emission 
in a fluorescence microplate reader, and results were 
analyzed in Excel.
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expression of PcNa and caspase-3
Further to the evaluation of the inhibitory effects of SurR9-
C84A on undifferentiated SK-N-SH cells, immunofluorescence 
for the proliferative marker PCNA and the apoptotic marker 
Caspase-3 was studied. Cells were seeded at 105 cells/well in 
the BD Falcon eight-well culture slide following the protocol, 
as described previously.14 Cells were synchronized by the 
addition of nocodazole (70 ng/mL) for 12 hours, washed, and 
then incubated for 65 minutes to enrich the anaphase and telo-
phase population. Then, the cells were subjected to NP treat-
ment corresponding to protein concentrations of 25, 50, 100, 
and 200 µg/mL for 24 hours. In order to compare the effect, 
cells treated with non-nano-SurR9-C84A (75 µg/mL) were 
included in the study along with the void and untreated 
controls. After treatment, cells were washed thrice in PBS, 
followed by fixation in 4% paraformaldehyde for 15 minutes. 
Cells were permeabilized with 0.1% Triton X-100 in PBS, 
followed by blocking with 2% rabbit serum.
Then, the undifferentiated cells were incubated with the 
mouse monoclonal anti-PCNA (1:100; Sigma-Aldrich) and 
rabbit anti-Caspase-3 (1:100; Cell Signaling Technology, 
 Danvers, MA, USA) for 1 hour. FITC-labeled rabbit anti-
mouse (1:100; Sigma Aldrich) and goat anti rabbit (1:100) 
were used as secondary antibodies. The cell nucleus was 
stained with PI (1:500) for 30 minutes and mounted with 
mounting media. Further imaging was carried out using the 
Leica SP5 confocal microscope at 40× magnification.
In vitro proliferation in differentiated  
sK-N-sh cells
expression of PcNa and Ki67
To evaluate the proliferative potential of SurR9-C84A on 
differentiated SK-N-SH cells, immunofluorescence for 
the proliferative markers PCNA and Ki67 were studied. 
Cells were seeded at 105 cells/well in BD Falcon eight-
well culture slides following the protocol described for the 
 undifferentiated cells. After treatment with SurR9-C84A, the 
differentiated cells were incubated with mouse monoclonal 
anti-PCNA and mouse anti-Ki67 (1:100; Sigma-Aldrich) 
for 1 hour at 37°C. FITC-labeled rabbit antimouse and goat 
antirabbit (1:100) were used as secondary antibodies. The 
cell nucleus was stained with PI (1:500) for 30 minutes, and 
further imaging was carried out using the Leica SP5 confocal 
microscope at 40× magnification.
Bromodeoxyuridine (BrdU)-labeling assay
The proliferating potential of NP-loaded SurR9-C84A was 
evaluated on retinoic acid-differentiated SK-N-SH cells. 
Cells were seeded at a density of 2×104 cells/well in a 96-well 
plate, and differentiation was induced for 12–14 days and 
was confirmed with the detection of neurite processes. 
Then, the cells were treated with SurR9-C84A-loaded 
NPs corresponding to protein concentrations of 50, 100, 
and 200 µg/mL for 24 hours. Void treatment and untreated 
controls were also included. The entire protocol was followed 
as per the manufacturer’s indications for the BrdU Labeling 
and Detection Kit III (Roche, Basel, Switzerland). In brief, 
after treatment, cells were incubated with the BrdU-labeling 
solution for 6 hours, followed by fixation with a precooled 
fixative (ethanol in HCl). Then, the cells were incubated with 
peroxidase-conjugated anti-BrdU for 30 minutes, after which 
the peroxidase substrate was introduced. The absorbance was 
measured using a microplate reader at 405 nm, keeping the 
wavelength 490 nm as a reference.
gene-expression study
To define the dual mechanistic actions of SurR9-C84A 
(apoptotic effect on undifferentiated cells and proliferative 
effect on differentiated cells), quantitative real-time poly-
merase chain reaction (qRT-PCR) analysis was conducted 
for wild-type survivin, Caspase-9, Caspase-3, Caspase-8, 
Caspase-7, Cytochrome-C, TRAIL, β-tubulin III, p53, and 
cyclin D1. Undifferentiated and differentiated SK-N-SH cells 
were grown confluent in six-well plates and then treated with 
void and SurR9-C84A-loaded NPs (corresponding to protein 
concentrations of 50, 100, and 200 µg/mL). An untreated 
control and pure protein-treated wells were also included in 
the study. After treatment, ribonucleic acid (RNA) was iso-
lated from the cells following the protocol supplied with the 
reagent (TRIzol®; Thermo Fisher Scientific). Complementary 
deoxyribonucleic acid (cDNA) was prepared from the total 
RNA extracted using SuperScript III reverse transcriptase, 
oligo-deoxy-thymine, and RNase-free water (Thermo Fisher 
Scientific). The prepared cDNA was used for gene-expression 
studies as described previously.14 In brief, 15 µL of the reac-
tion mixture was prepared using the SYBR green PCR master 
mix (Bio-Rad Laboratories Inc.,) and underwent qRT-PCR 
using an iCycler™ (Bio-Rad Laboratories Inc.,). In this study, 
duplicate samples were run for the said genes, and a mean 
threshold-cycle value was used for the calculation.
The 2−ΔΔCt method was adopted for quantification, while 
gene amplification was verified by melt-curve analysis and 
visualized by ethidium bromide-stained 1% agarose gel.14 
A complete list of the primer sequences is given in Table 1. 
Gene expression was studied with actin as an internal 
reference.
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Table 1 list of primer sequences used in the study
Gene Forward primer (5′ to 3′) Reverse primer (3′ to 5′) Reference
1 β-Actin cTcaccgagcgcggcTaca cTccTgcTTgcTgaTccacaT 14
2 Survivin ccaccgcaTcTcTacaTTca TaTgTTccTcTaTggggTcg 14
3 Caspase-3 cTcggTcTggTacagaTgTcgaTg ggTTaacccgggTaagaaTgTgca 64
4 Caspase-8 gggacaggaaTggaacacac cagcaagggaagggcacTTc 65
5 Caspase-9 cTgcgaacTaacaggcaagc cTagaTaTggcgTccagcTg 66
6 Cyclin D1 gaacaaacagaTcaTccgcaa cccTTcTggTaTcaaaaTgc 14
7 BAX ggcccaccagcTcTgagcaga gccacgTgggcgTcccaaagT 67
8 p53 cagccaagTcTgTgacTTgcacgTac cTaTgTcgaaaagTgTTTcTgTcaTc 65
9 Caspase-7 agTgacaggTaTgggcgTTcg gcaTcTaTccccccTaaagTgg 66
10 Cytochrome-C TgggTgaTgTTgagaaagg cggcTgTgTaagagTaTcc 68
Flow cytometry and protein expression
Propidium iodide staining
The percentage of dead cells after treatment with SurR9-
C84A-loaded NPs was evaluated by flow-cytometry analysis 
of PI-stained cells. In brief, both the undifferentiated and 
differentiated SK-N-SH cells were plated in six-well culture 
plates and were grown confluent, followed by treatment 
with protein-loaded NPs at concentrations of 25, 50, 100, 
and 200 µg/mL for 24 hrs. An untreated control and void 
NP-treated cells were also included in the study. After treat-
ment, the cells were washed with ice-cold PBS (pH 7.4), 
trypsinized, and centrifuged at 800 rpm for 5 minutes. Cell 
pellets were collected in six separate centrifuge tubes, cor-
responding to the treatments, and were added to 500 µL of 1× 
PBS containing 2% FBS. Cells were stained with 25 µL 
of a 50 µg/mL concentration of PI and incubated at 4°C 
for 30 minutes, and fluorescence was recorded using a 
FACS™ cell sorter (BD Biosciences) and data acquired using 
FACSDiva™ software (BD Biosciences).
annexin V FITc staining
SK-N-SH cells (both undifferentiated and differentiated) 
grown confluent in the six-well plates were treated with 
SurR9-C84A-loaded NPs at concentrations corresponding 
to 50, 100, and 200 µg/mL of the pure protein for 24 hours. 
An untreated control, void-, and pure survivin (75 µg/mL)-
treated wells were also included in the study.
After treatment, cells were washed in ice-cold PBS, 
trypsinized, and incubated separately for 10 minutes with the 
reaction mixture (consisting of incubation buffer, Annexin-
V-Fluos labeling reagent, and propidium iodide), prepared as 
per the manufacturer’s protocol (Annexin-V-Fluos staining 
kit; Roche). Fluorescence signals were detected at excitations 
of 488 nm and emissions at 510±30 and 600±30 for annexin 
and PI, respectively, using the flow cytometer (BD Biosci-
ences) equipped with FACSDiva software.
Protein expression
After treatment with undifferentiated and differentiated 
SurR9-C84A, SK-N-SH cells were evaluated for the expres-
sion of apoptotic and proliferative markers through flow-
cytometry analysis. Initially, undifferentiated SK-N-SH 
cells were studied for the expression of BAX, Cyt-C, and 
Cas-3 to determine the intrinsic apoptotic cascade. Follow-
ing this, endogenous levels of survivin, β-tubulin, PCNA, 
and Ki67 were also estimated. Considering the proliferative 
potential of SurR9-C84A, differentiated SK-N-SH cells 
were mainly evaluated for the cell-division markers PCNA, 
β-tubulin, endogenous survivin, and Ki67. Also, the apop-
totic proteins described earlier were also included for the 
differentiated cells.
statistics
Statistical differences were calculated using Student’s t-test, 
and results were considered to be statistically significant 
with P0.05.
Results
The mutant variety of SurR9-C84A competitively antago-
nized the actions of cell division and apoptosis exhibited 
by wild-type survivin overexpressed in cancers. It also has 
significant therapeutic potential in promoting the prolifera-
tion of differentiated neuroblastoma cells (neuronal origin) 
that have no/negligible expression of survivin.14 Therefore, 
SurR9-C84A can be suitably applied to cut down on pro-
liferation in brain cancers (neuroblastoma in this case) and 
provoke proliferation in differentiated neurons. Considering 
the limitations of protein delivery, the prime goal of this study 
was to formulate a novel polymeric nanodelivery system that 
would enhance protein stability and thereby its half-life. The 
use of PLGA offered the safest delivery on account of its bio-
degradability, and physicochemical characterization revealed 
salient features of this novel nanoformulation. The technique 
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of modified double emulsion provided enough control on the 
process parameters, with a size range not exceeding 150 nm 
and a protein encapsulation of 81%.21
Physicochemical characterization: 
protein purification, particle size, surface 
morphology, and drug encapsulation
Protein purification was performed using column chro-
matography, and purity was checked against SDS-PAGE 
 electrophoresis and later confirmed with Western blot 
(Figure 1, A and B). Average particle size determined by 
dynamic light scattering was around 100–150 nm, a range 
ideal for the delivery of drugs through the blood–brain bar-
rier. Surface morphology was smooth and spherical with 
uniform size distribution, as determined by SEM for both 
the void (Figure 1C) and protein-loaded NPs (Figure 1D). 
As seen in Table 2, the average encapsulation efficiency was 
found to be 80.9%, with a loading of 3.2%.
The protein encapsulation is in agreement with approxi-
mately 1 mg of the drug-loaded NP powder corresponding 
to 25 µg of SurR9-C84A that is encapsulated. In general, pep-
tides and proteins frequently display hydrophilic behavior, 
and entrapping them in the hydrophobic polymer matrix is 
often challenging. In our study, a reasonably high encapsula-
tion of 81% was achieved employing the principle of modified 
double emulsion, where the protein was initially solubilized in 
the internal aqueous phase, avoiding protein dispersion should 
the single-emulsion technique be employed.22 Also, the ionic 
interactions generated between the positively charged amino 
groups (NH2+) and the negatively charged carboxyl groups 
(COO-) of the acid-terminated surface of the PLGA polymer 
accounted for the enhanced drug entrapment.23,24
release kinetics
Protein release from the nanoformulation is represented in 
Figure 1E. A biphasic protein-release pattern was observed 
at different pH values. A burst release of 63% was observed 
within 6 hours at pH 7.4, while the release rate remained 
sustained after 12 hours and reached saturation in 4 days. 
At pH 2, the burst release was observed to be 77% 
within 6 hours, and the release pattern did not maintain 
 similar consistency to that found at pH 7.4. The initial high 
burst effect was due to drug diffusion from the polymer 
matrix (reduced diffusion-path length), and also because NPs 
in the small size range of 150 nm offer a higher surface-to-
volume ratio, facilitating the enhanced release of protein that 
is near or on the NP surface.25 This can also be explained as 
the drug release from the PLGA polymer being influenced by 
the ratio of the lactide and glycolide content. The lower ratio 
in PLGA (50:50) imparts hydrophilicity, water absorbance, 
and faster degradation rates compared to the slower drug-
release profiles with lactide-rich PLGA (85:15).
In addition, acidic conditions hasten PLGA degradation, 
which in turn enhances autocatalysis due to the accumulation 
of lactic and glycolic acids. Therefore, the burst release at 
acidic pH was higher compared to the neutral pH.17,26 The 
sustained effect observed after 12 hours requires the com-
bined effect of both diffusion and degradation of the polymer 
matrix for protein release.25 On the whole, it was shown that 
the molecular weight, copolymer ratio, pH, and surface area 
of the NPs strongly influenced protein release.
Polymer–protein interaction
Figure 1F shows the DSC-curve patterns for the freeze-dried 
void and protein-loaded PLGA NPs. A peak was observed 
at 52°C for both void and protein-loaded NPs, indicating 
the endothermic peak for the PLGA polymer. The follow-
ing inference was made from the DSC curve obtained. The 
absence of a discrete melting point suggested the amor-
phous nature of the polymer, and also its thermal stability 
was observed up to 250°C. No significant difference was 
observed for the DSC curves of the void and protein-loaded 
NPs, indicating that the protein was encapsulated within the 
polymer without affecting its integrity. The absence of a 
crystalline peak also suggested the amorphous phase of the 
protein encapsulated inside the NPs.27,28
Fourier-transform infrared spectroscopy
FTIR spectroscopy is a valuable tool in characterizing 
protein binding and integrity once encapsulated within the 
NPs. Figure 1G shows the FTIR spectra for the void and 
SurR9-C84A-loaded PLGA nanoparticles. As observed, the 
bands detected at 1,650 cm-1 and 1,540 cm-1 confirm protein 
encapsulation within the NPs and represent the amide I and II 
bands, respectively. These bands arise due to the correspond-
ing C=O and N–H stretch vibrations in the amide linkages 
of the protein. FTIR analysis also confirmed the intactness 
of the protein secondary structure during the process of NP 
formation and that the protein integrity was preserved.29
Table 2 Encapsulation efficiency (EE) and the percentage of 
surr9-c84a loading in the Plga NPs
Polymer  
weight
Protein  
weight
Supernatant  
protein weight
EE  
(%)
Loading  
(%)
EE/loading  
average (%)
1 50 mg 2.05 mg 0.36 mg 82.4 3.38 80.9±1.22
2 50 mg 1.9 mg 0.39 mg 79.4 3.02 3.2±0.14
Abbreviations: Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles.
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sDs-Page for protein integrity
Figure 1H shows the presence of a 16 KDa band characteristic 
of SurR9-C84A. The harsh parameters involved in the NP-
preparation process, such as the organic solvents, sonication, 
and emulsification, might have resulted in the denaturation 
of the protein.
As observed in the figure, the structure of the protein was 
intact, and no additional bands were detected, though there 
are studies reporting the degradation and protein hydrolysis 
when encapsulated in PLGA polymer.30–32 The modified 
double-emulsion technique employed in this study proved 
to be effective in successful encapsulation of the protein 
without denaturation.
Determination of NP-internalization  
and -uptake mechanism
In vitro NP-uptake studies
Figure 2, A–D shows the uptake of rhodamine-labeled NPs 
in differentiated and undifferentiated SK-N-SH cells. The 
histogram (Figure 2E) shows a time-dependent increase of 
NP internalization in both types of cells. The idea behind 
the NP-uptake study in SK-N-SH cells was that it serves 
as a useful model for evaluating the in vitro efficacy of 
SurR9-C84A for neurological diseases.33 As observed in 
Figure 2A–D, the number of NPs interacting with the cell 
membrane increased with time, as did their internalization. 
The significant feature of these NPs was the rapid uptake 
by the cells, where 40%–45% of them were internalized 
within 30 minutes of incubation. This could be explained by 
the small size range (100–150 nm) of the NPs. As observed 
from the confocal images, the presence of rhodamine-labeled 
NPs (red) around the nucleus (blue, stained by DAPI) 
confirmed the presence of NPs in the cytoplasm and their 
internalization.
retinoic acid-induced differentiation  
in sK-N-sh cells
Retinoic acid (20 µM) induced morphological changes 
from day 2 of its addition, followed by distinct induction of 
neurite processes in N-subtype cells. Cells were considered 
to be fully differentiated if they developed neurite processes 
longer than their cell bodies. Figure 2F shows the undiffer-
entiated cells, and differentiation was achieved after 12 days 
of treatment with conditioned media (Figure 2G).
NP-uptake mechanism
Cellular uptake of NPs involves a variety of endocytic mech-
anisms, including clathrin-mediated, caveolae- dependent, 
and independent endocytosis and macropinocytosis. 
In order to determine the precise mechanism of uptake, 
 incubation with the corresponding inhibitors revealed inter-
esting results. Chlorpromazine, a clathrin endocytic inhibitor, 
showed a 40% reduction in uptake compared to the void and 
SurR9-C84A-loaded NPs, while indomethacin showed no 
difference. Slight reductions in uptake were observed after 
sodium azide (44.2%) and colchicine (35.5%) treatment, 
indicating that the uptake of PLGA NPs in differentiated 
SK-N-SH was through clathrin-mediated endocytosis along 
with macropinocytosis and energy involvement (Figure 2N). 
Macropinocytosis is a physiological function utilized by 
cells for extracellular fluid turnover, and involvement of 
this process in uptake indicates that a few percent of NPs 
were internalized within the cells devoid of cell-surface 
interaction. This also signifies escape from macrophage 
phagocytosis.34
Flow-cytometric analysis (Figure 2, H–M) also revealed 
similar results, where cells pretreated with chlorpromazine 
showed only 8.1% uptake compared to 24.8% of only 
PLGA-treated controls. Pretreatments with indomethacin 
(Figure 2J) showed no change, while colchicine reduced 
uptake to 14.7%, confirming the involvement of clathrin and 
macropinocytosis-uptake mechanisms.
Wild-type survivin expression in differentiated  
and undifferentiated sK-N-sh cells
As observed in Figure 2O, undifferentiated SK-N-SH cells 
showed almost 95% wild-type survivin expression, indicat-
ing the substantial role of survivin in proliferation, while 
the differentiated cells (Figure 2P) showed no or negligible 
expression, confirming lowered proliferative potential.
In vitro cytotoxicity in undifferentiated 
sK-N-sh cells
expression of PcNa and cas-3
PCNA is a proliferation marker expressed at the G
2
/M cell-
cycle phase marking the significant influence of wild-type 
survivin in provoking cell division.14 In this study, we aimed 
to evaluate the mechanism by which the SurR9-C84A acts 
and inhibits proliferation, leading to cell-cycle arrest and 
eventually ending up with apoptosis. In Figure 3, A and 
B, a concentration-dependent increase in the expression of 
Cas-3 and vice versa with PCNA (Figure 3, C and D) was 
observed. This indicates the antagonistic effects of SurR9-
C84A after dimerization with wild-type survivin, followed 
by the blockade of its functioning. Therefore, cells arrested 
in mitosis (G
2
/M) overexpress Cas-3, eventually ending up 
in cell death (Figure 3E).35
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Figure 2A–P Determination of NP internalization and uptake mechanism.
Notes: (A, B) Undifferentiated and (C, D) differentiated sK-N-sh cells. cells were incubated with surr9-c84a NPs, and within 1 hour NPs accumulated around the 
perinuclear spaces, followed by nuclear localization in 2 hours. arrows represent the rhodamine-labeled NPs. (E) histogram representing average ± standard deviation of 
the NPs present inside the cells counted in five different fields. (F) sK-N-sh cells before and (G) after treatment with retinoic acid 20 µM. cells were considered to be 
differentiated with the development of neurite processes, as indicated with arrowheads. (H–M) Flow cytometry confirming the NP-uptake mechanism through clathrin-
mediated endocytosis. Chlorpromazine a clathrin-mediated endocytic inhibitor showed significant (2.5-fold) reduction in the uptake compared to the controls, while sodium 
azide and colchicine lowered uptake by 1.7- and 1.5-fold, respectively. Thus, it confirmed the involvement of energy dependent and macropinocytosis uptake mechanisms. 
(N) The NP-uptake mechanism was redetermined by pretreating the cells with the endocytic inhibitors chlorpromazine (10 µg/ml, clathrin-mediated endocytosis), 
indomethacin (10 µg/ml, caveolae-mediated endocytosis), sodium azide (2 µg/ml), and colchicine (5 µg/ml, pinocytosis) for 1 hour, followed by rhodamine-labeled NPs 
incubation for 4 hours at 1 mg/ml concentration. after treatment, cells were washed with phosphate-buffered saline to remove free NPs, and then the cells were lysed with 
1% Triton-X in 0.2 M NaOH. The resulting fluorescence was measured at 530 nm excitation and 630 nm emission, and the corresponding weights of the NPs were calculated 
from the standard graph plotted for rhodamine-labeled NPs. (O) Merge images showing the expression of wild-type survivin in differentiated and (P) undifferentiated sK-
N-SH cells. Undifferentiated cells showed the maximum expression of survivin, confirming proliferation, while negligible expression was observed in differentiated SK-N-SH 
cells, indicating a poor proliferation rate. *P0.05; **P0.01 (student’s t-test).
Abbreviation: NPs, nanoparticles.
live and dead cell assay
This assay was conducted to determine the cytotoxic potential 
of the SurR9-C84A-loaded NPs toward SK-N-SH cells. As 
seen in Figure 3F, the protein-loaded NPs were prominent 
in exerting the cytotoxic effect, as 50 µg/mL of the SurR9-
C84A-loaded NPs was equally effective compared to pure 
protein (75 µg/mL). This could have been because of the 
enhanced stability and half-life of the protein encapsu-
lated in the nanoformulation compared to its free form. 
A  dose-dependent effect of protein loaded NPs was also 
evident with the increased percentage of dead cells.
cell-proliferation study
The DNA content exhibited by individual cells is constant, 
and hence in this assay, the fluorescence-intensity measure 
of DNA corresponds to the cell number, and thus gives a 
measure of cell proliferation.36 As seen in Figure 3G, SurR9-
C84A exhibited proliferation inhibition in undifferentiated 
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Figure 3A–K schematic representation of antitumor effects of surr9-c84a-loaded NPs in undifferentiated sK-N-sh cells.
Notes: caspase 3 (cas-3) expression in undifferentiated sK-N-sh cells after treatment for 24 hours in (A) control and (B) surr9-c84a treatments. a dose-dependent 
increased expression of Cas-3 was evident with the treatments, indicating the follow-through of apoptosis. Cas-3 expression is shown in the fluorescein isothiocyanate (FITC) 
channel (green), indicated by arrowheads, and evident in the protein-treated cells compared to the control. The nucleus is stained red with propidium iodide (PI), and bright-
field (BF) and merge images are also shown. (C, D) PcNa expression in undifferentiated sK-N-sh cells after treatment for 24 hours with surr9-c84a-loaded NPs. a dose-
dependent decreased expression of PcNa was evident with the treatments in undifferentiated sK-N-sh cells. PcNa expression is shown in the FITc channel (green), and 
the nucleus is stained red with PI. BF and merge images are also shown. all the images were taken at 40×. (E) histogram representing means ± standard deviation of PcNa 
expression in cells counted in five independent fields. (F) Percentage of cells alive and dead after treatment with surr9-c84a-loaded NPs for 24 hours. cells were seeded in 
96-well plates, and after treatment live and dead cell assays were performed to determine the percentage of cells alive and dead, as per the instructions. NP-loaded surr9-c84a 
(50 µg/ml) was equally effective compared to the 75 µg/ml concentration of pure surr9-c84a (without NPs) included in the study. (G) The percentage proliferation of cells 
was determined through cyQuant assay. The NP-treated cells showed a dose-dependent decrease in proliferation, with almost 50% reduction posttreatment. Fetal bovine 
serum (FBs; 20%) was used as a positive control. (H) annexin-V-Fluos staining for the untreated controls; (I) surr9-c84a-loaded NP-treated cells. The treatment group 
showed 31.8% cell death. (J) PI staining for the untreated controls; (K) surr9-c84a-loaded NP-treated cells. surr9-c84a-treated groups showed 84.8% positivity for PI, 
indicating its cytotoxic potential. *P0.05. Data are presented as means ± standard deviation, n=3.
Abbreviations: NPs, nanoparticles; Pe, phycoerythrin; PcNa, proliferating cell nuclear antigen.
SK-N-SH (neuroblastoma) cells in a concentration-dependent 
manner, with almost half of the cells (56%) wiped out 
at 100 µg/mL concentration.
In vitro proliferation in differentiated  
sK-N-sh cells
expression of proliferation markers PcNa  
and Ki67 and BrdU assay
The proliferative potential of SurR9-C84A on differentiated 
SK-N-SH cells was studied by confirming the expression of 
PCNA (Figure 4, A and B) and Ki67 (Figure 4, D and E). 
PCNA was expressed at the G
2
/M phase of the cell cycle, 
while Ki67 was expressed at all active phases of cell divi-
sion except at the resting phase (G
0
).37 Therefore, these 
are both excellent markers for determining proliferation 
in differentiated SK-N-SH cells. Dividing cells were also 
determined utilizing the BrdU assay, which is an excellent 
method of monitoring cell proliferation. BrdU is an analog 
of thymidine, and gets incorporated into the DNA of the 
dividing cells. Consequently, many studies have reported 
the use of BrdU labeling for determining cell proliferation, 
particularly neurons.38
After treatment with SurR9-C84A, 23.2% of the differen-
tiated SK-N-SH cells expressed PCNA, while 16% of them 
were found positive for Ki67. Also, when compared with the 
controls, BrdU labeling was found to be increased by 1.15-
fold after SurR9-C84A treatment (Figure 4F). Together, 
these results confirm that the differentiated SK-N-SH cells, 
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Figure 4A–J Proliferative and neuroprotective potential of surr9-c84a on differentiated sK-N-sh neuronal cells.
Notes: Differentiated sK-N-sh cells were observed for expression of the proliferating markers PcNa and Ki67 in (A, D) untreated control and (B, E) surr9-c84a-treated 
cells after treatment for 24 hours. Dose-dependent increased expression of PcNa and Ki67 was evident with the treatments in differentiated sK-N-sh cells. PcNa and 
Ki67 expression is shown in the fluorescein isothiocyanate (FITC) channel (green), and the nucleus is stained red with propidium iodide (PI). Bright-field (BF) and merge 
images are also shown. The arrow heads represent the PcNa expression. all the images were taken at 40×. (C) histogram of means ± standard deviation of PcNa and Ki67 
expression in the cells counted in five independent fields. (F) Bromodeoxyuridine (BrdU) assay in differentiated sK-N-sh cells after surr9-c84a treatment. BrdU is an analog 
of thymidine, and dividing cells incorporate it into their deoxyribonucleic acid. Therefore, cells that are BrdU+ indicate proliferation and is concentration-dependent with the 
treatments. (G) annexin-V-Fluos staining for the untreated controls, and (H) surr9-c84a-loaded NP-treated cells. The treatment group were 98.1% annexin–, indicating 
the cytoprotective nature of surr9-c84a. (I) PI staining for the untreated controls, and (J) surr9-c84a-loaded NP-treated cells. surr9-c84a-treated groups showed no 
significant difference for PI, indicating its neuroprotective potential. *P0.05; **P0.01. Data are represented as means ± standard deviation, n=3.
Abbreviations: NPs, nanoparticles; Pe-a, propidium iodide signal.
which were deficient in wild-type survivin, regained their 
proliferation when treated with SurR9-C84A.
Flow-cytometry PI and annexin V FITc staining
Apoptotic cells are typically characterized by DNA fragmenta-
tion, followed by a significant loss of DNA content. PI staining 
is specific to DNA, and thereby provides a rapid estimation 
of the percentage of dead cells.39 As observed from Figure 3, 
H–K, a significant amount of dead cells was observed with 
the SurR9-C84A-treated undifferentiated cells compared to 
the untreated controls, and the trend was concentration-
 dependent. Figure 3, I–K, shows 30.8% of annexin+ and 84.8% 
of PI+ cells, respectively, indicating the percentage of apoptotic 
cells. In contrast, the percentage of dead cells was significantly 
reduced (98% annexin- and 69.5% PI- cells) after SurR9-C84A 
treatment in differentiated SK-N-SH cells (Figure 4, G–J).
gene-expression study
To confirm the characteristic mechanism of SurR9-C84A on 
undifferentiated and differentiated SK-N-SH cells, qRT-PCR 
was performed for the proliferative (wild-type survivin) and 
the apoptotic genes for Cas-3, -7, -8, and -9, Cyt-C, and p53. 
In the case of undifferentiated SK-N-SH cells, the apoptotic 
genes Cas-3, -7, -8, and -9, Cyt-C, and p53 showed 1.32-, 
1.54-, 2.39-, 1.55-, 2.84-, and 1.2-fold increases, respectively, 
while the proliferative marker endogenous survivin showed 
a twofold reduction, confirming the antitumor potential of 
SurR9-C84A.
When studied in differentiated SK-N-SH cells, the same 
apoptotic genes for Cas-8, Cas-9, and p53 showed 1.53-, 1.58-, 
and 3.33-fold reduced expression.  Further, endogenous 
survivin levels showed a 1.1-fold increase in expression, 
provoking proliferative potential (Figure 5, A–D).
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Figure 5 gene-expression study in (A) undifferentiated and (B) differentiated sK-N-sh cells after surr9-c84a treatment.
Notes: surr9-c84a showed increased expression of apoptotic genes in undifferentiated cells, whereas a reduced expression of them was noticed in differentiated sK-N-sh 
cells. The relative expression of all the genes was measured and calculated relative to the housekeeping gene β-actin. Data are represented as means ± standard deviation of 
two independent experiments. (C) gel images of gene expression in undifferentiated and (D) differentiated sK-N-sh cells. lanes 1–6 are control, void, pure surr9-c84a 
75 µg, and surr9-c84a-loaded NPs with 50, 100, and 200 µg treatments, respectively. *P0.05; **P0.01.
Abbreviation: NPs, nanoparticles.
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Protein expression
SurR9-C84A showed dual but distinct actions on undiffer-
entiated and differentiated SK-N-SH cells that represented 
tumorous and neuronal characteristics. The apoptotic 
markers p53, BAX, Cyt-C, and Cas-3 were upregulated 
by 77.4%, 90.9%, 4.5%, and 14%, respectively, indicating the 
antitumor effects of SurR9-C84A. Also, the proliferative mark-
ers β-tubulin, survivin, PCNA, and Ki67 were downregulated 
by 34.5%, 79%, 25.88%, and 15%, respectively (Figure 6A). 
These results were consistent with our earlier results of the 
antitumor activities of SurR9-C84A.12 Owing to the prolifera-
tive potential of SurR9-C84A in neurons with a low endog-
enous pool of survivin, differentiated SK-N-SH cells exhibited 
upregulation of cell-division markers. Endogenous survivin 
levels increased up to 46.3%, while PCNA and Ki67 showed 
a 5.1% and 24.9% increment, respectively. Substantiating this, 
the apoptotic markers Cyt-C, Cas-3 and p53 showed a respec-
tive reduction by 65.6%, 54.5%, and 74.5%, respectively. 
Also, the specific neuronal differentiating marker β-tubulin 
III showed a 3.7% downregulation, indicating the change of 
differentiation phase to proliferation (Figure 6B). Given these 
dual actions, SurR9-C84A holds promising potential for a 
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Figure 6 comparison of protein expression in the undifferentiated and differentiated sK-N-sh neurons.
Notes: (A) Protein expression in undifferentiated sK-N-sh after treatment with surr9-c84a-loaded NPs. compared with the untreated control, the proteins involved in 
cell-cycle progression, such as survivin, PcNa, Ki67, and β-tubulin, were downregulated, and the apoptotic markers BaX, cyt-c, cas-3, and p53 were upregulated after 
SurR9-C84A treatment. This confirmed the antitumor potential of SurR9-C84A. (B) surr9-c84a increased the expression of cell-proliferation markers, such as β-tubulin, 
survivin, PcNa, and Ki67 in differentiated sK-N-sh cells, while indicators of apoptosis cas-3, cyt-c, and p53 showed reduced expression compared to the controls. also, 
the differentiating marker β-tubulin III showed a slight reduction, indicating the preparatory changes toward proliferation.
Abbreviations: FITc, fluorescein isothiocyanate; NPs, nanoparticles; PCNA, proliferating cell nuclear antigen.
variety of neurological ailments. A comparative analysis of 
various proteins studied for undifferentiated and differentiated 
SK-N-SH cells is given in Table 3.
Discussion
The understanding of various neurological disorders rang-
ing from brain tumors to neurodegeneration has undergone 
rapid improvement in recent times. Despite the differences 
in these pathologies, the ultimate result is the irreversible 
death or degeneration of the neurons.40 Therefore, an ideal 
therapeutic differentially inducing apoptosis in brain tumor 
cells and provoking proliferation in neurons would poten-
tially serve the demand. In this study, we have reported the 
comparative effects of SurR9-C84A on tumorous undiffer-
entiated SK-N-SH and the neuronal differentiated SK-N-SH 
cells for the first time. Tumor cells due to overexpression of 
survivin proliferate indefinitely, while the postmitotic cells 
like the neurons (differentiated SK-N-SH in this case) were 
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Table 3 comparative protein expression in undifferentiated and differentiated sK-N-sh cells
Stained for Undifferentiated  
SK-N-SH
Remarks Differentiated 
neurons
Remarks
1 annexin-V-Fluos 30.8%+ apoptosis 98%- reduced apoptosis
2 PI 84.8%+ apoptosis 69.5%- reduced apoptosis
3 PcNa 25.8%↓ reduced proliferation 5.1%↑ Initiation of cell division
4 Ki67 15%↓ reduced proliferation 24.9%↑ Initiation of cell division
5 Wild-type survivin 79%↓ reduced proliferation 46.3%↑ Initiation of cell division
6 cas-3 14%↑ apoptosis 54.5%↓ reduced apoptosis
7 cyt-c 4.5%↑ Intrinsic apoptotic pathway 65.6%↓ reduced apoptosis
8 BaX 90.9%↑ apoptosis –
9 β-Tubulin 34.5%↓ reduced microtubule dynamics 77%↑ enhanced microtubule stability
10 p53 77.4%↑ apoptosis 74.5%↓ reduced apoptosis
11 β-Tubulin III – 3.7%↓ Initiation of cell division
Abbreviations: PI, propidium iodide; +, positive; - , negative; ↑, fold increase; ↓, fold decrease; PcNa, proliferating cell nuclear antigen.
deficit in the endogenous pool and showed reduced or no 
proliferation.14,41 We also observed similar results where 
undifferentiated and differentiated SK-N-SH cells showed 
higher and lower expression of survivin, respectively. In 
terms of cancer therapeutics, survivin is an attractive target 
on account of its tumor-specific expression compared to 
normal cells, except the testis and endometrium. Tumor-
specific expression is also highly unlikely for any of the 
IAPs studied so far.5,42 Wild-type survivin is overexpressed 
in tumor cells, with the potential to regulate cell division and 
apoptotic mechanisms.18,43 Several reports have confirmed 
that agents acting against survivin, such as small-molecule 
inhibitors, antagonists, and antisense agents, interfere 
with survivin expression or function and suppress tumor 
progression.12,18,44,45 Studies have also reported that survivin 
overexpression is responsible for the resistance developed in 
advanced tumors.5,46 Therefore, in a clinical setting, interfer-
ing with the functions of wild-type survivin results in strong 
antitumor activity, and for this purpose baculovirus inhibitory 
apoptotic protein repeat (BIR)-motif mutant SurR9-C84A-
loaded NPs were employed against the neuroblastoma cell 
lines. Owing to the difficulty in delivering protein drugs in 
terms of their physicochemical stability, bioavailability, and 
biological half-life, etc,16 we tried to encapsulate SurR9-
C84A in biodegradable polymeric PLGA NPs. Moreover, 
PLGA NPs are biodegradable and biocompatible, yielding 
lactic and glycolic acids that in turn are converted to nontoxic 
carbon dioxide and water. The PLGA polymer employed in 
this study had an equal copolymer polylactic acid (PLA) and 
polyglycolic acid (PGA) ratio, and thus it showed initial burst 
followed by sustained release.47–49 The significant feature 
of this nanoformulation was that it showed internalization 
within 30 minutes of incubation and was found to accumulate 
in the perinuclear spaces and also in the nucleus (Figure 2, 
A–D). Interestingly, when treated with SurR9-C84A, undif-
ferentiated SK-N-SH cells showed reduced proliferation in a 
concentration-dependent manner, confirmed by the reduced 
expression of endogenous survivin and proliferation markers 
PCNA and Ki67 (Figure 3).  Several studies also reported sim-
ilar results, where cytotoxicity of tumor cells was observed 
upon interfering with survivin using dominant-negative 
survivin mutants, antisense oligonucleotides, and small inter-
fering RNA.18,44,45,50 In accordance with the previous results, 
we also observed increased expression of the apoptotic genes 
for Cas-3, Cas-8, and Cas-9, with a simultaneous downregu-
lation of wild-type survivin in a dose-dependent manner in 
undifferentiated cells (Figure 5, A and C). Based on the 
data published on the selective role of wild-type survivin in 
antagonizing the mitochondria-mediated intrinsic apoptotic 
pathway,51 we chose to confirm the mechanistic SurR9-C84A 
apoptosis by studying the expression of Cyt-C, Cas-3, and 
Cas-9. In addition, molecular antagonists targeting wild-type 
survivin preferentially mediate the mitochondria-dependent 
apoptosis followed by Cas-9 activation.52–54 Therefore, we 
studied the expression of Cas-3 and Cas-9, and ascertained 
the following apoptotic mechanism for SurR9-C84A.
As indicated, SurR9-C84A displaced the overexpressed 
wild-type survivin, leading to mislocalization and disturbed 
microtubule dynamics and catastrophic effects, eventually 
culminating in cell death. It also interfered with the forma-
tion of the survivin–SMAC/DIABLO complex, thereby 
relieving its inhibitory effect on Cas-9 activity.54 Also, 
due to the unavailability of wild-type survivin, hepatitis B 
X-interacting protein cannot alone inhibit the activation of 
procaspase-9, and thus propagates mitochondria-mediated 
apoptosis (Figure 7). Overexpression of cyclin D1 was 
also observed, owing to the cancerous nature of the neu-
roblastoma, which was consistent with the earlier results 
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Figure 7 surr9-c84a mechanism of action on undifferentiated and differentiated sK-N-sh cells.
Notes: In the case of undifferentiated cells, soon after the release of surr9-c84a from the NPs, they dimerized with wild-type survivin and antagonized its function, leading 
to cell-cycle arrest. surr9-c84a interfered with the formation of the survivin–sMac/DIaBlO complex, and thereby relieved survivin’s inhibitory effect on cas-9 activity. 
also, due to the unavailability of wild-type survivin, hepatitis B X-interacting protein (hXIaP) could not alone inhibit the activation of procaspase-9. levels of BaX, cyt-c 
and cas-9 also increased, followed by activation of cas-3, thus propagating mitochondria-mediated apoptosis. In the differentiated sK-N-sh cells, where there was a low 
endogenous pool of wild-type survivin, surr9-c84a was able to interact with the microtubular assembly and initiate chromosome passenger-complex formation, and thus 
neuronal division was initiated. This was evident from the expression of proliferation markers PcNa and Ki67.
Abbreviations: NPs, nanoparticles; cas-3, caspase-3; cPc, chromosome passenger complex; sMac/DIaBlO, second mitochondria-derived activator of caspases and 
direct IaP-binding protein with low PI; aPaF1, apoptotic protease activating factor 1; PcNa, proliferating cell nuclear antigen.
(Figure 5, A and C). Though cyclin D1 belongs to the 
category of oncogenes, overexpression of it indicates the 
initiation of programmed cell death. A number of studies 
have reported that cyclin D1 is overexpressed in postmi-
totic cells, including the neuroblastoma cell lines preced-
ing apoptosis.14,55 This has been explained as a specific 
selection strategy being exhibited by the cells toward the 
expression of cyclin D1, where moderate expression leads 
to overgrowth, while overexpression leads to apoptotic 
cell death.56 Similarly, the results were in agreement with 
increased expression of cyclin D1 being observed in undif-
ferentiated SK-N-SH cells and vice versa with differentiated 
cells. The mechanism can be explained as SurR9-C84A upon 
forceful expression displacing wild-type survivin from the 
microtubular assembly, leading to disturbed microtubular 
dynamics with increased expression of Cyt-C and Cas-3, as 
determined by the gene and protein study.
Proliferative effects of surr9-c84a
Apoptosis is the central mechanism of neuronal loss in 
various neurological diseases, and developing antiapoptotic 
 strategies to counteract it is a prime way of rescuing the 
neurons and preventing damage. Among the various anti-
apoptotic molecules studied, survivin, belonging to the IAP 
family, may find utility in the treatment of these diseases.
To begin with, survivin is a 16.5 kDa protein exhibiting 
dual actions on cell cycle and survival. Several studies have 
reported the essential role of survivin in premature brain 
development, and that defects in its expression exhibited 
abnormal brain hypoplasty and immature fetal deaths.4,57 
It was also reported to have neuroprotective effects where 
it colocalized with active Cas-3 and protected astrocytes 
after brain injury.58 Given the role of endogenous survivin 
in cell-cycle progression, it plays a prominent role in the 
spindle-fiber formation interacting with the microtubules and 
organizes the CPC, complexing with aurora B kinases and 
INCENP. Also, several reports exist on the role of survivin in 
premature brain development.4 Therefore, to address the issue 
of degenerative neurological diseases, a strategy of either 
neurogeneration or neuroprotection has to be employed. 
Agents acting against apoptosis like the inducers of Bcl-2 and 
IAPs have already gained attention for their protective 
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activity in preclinical studies.59,60 Therefore, survivin can be 
considered an attractive target for treating neurological dis-
eases, as it acts against apoptosis and provokes proliferation. 
Supporting this concept, one study observed that introduction 
of survivin restored neural progenitor cell proliferation in 
the brain, which was achieved by the modulating survivin 
expression or Wnt signaling.61 The neuroprotective activity 
of survivin was also confirmed in an in vitro model of mul-
tiple sclerosis, where mouse brain astrocytes were insulted 
with the BeAn strain of Theiler murine encephalomyelitis 
virus. Interesting results were reported with the upregula-
tion of survivin expression, where it formed a complex with 
the caspase-3 enzyme, nullifying the apoptotic events to be 
followed.62
Supportive data also exist on the cytoprotective actions of 
dominant-negative survivin M34 against the DNA-damaging 
induced agents.50,53 Given its protective potential, several 
mutant versions of wild-type survivin have been explored, 
of which the BIR-motif mutant known as dominant-negative 
survivin C84A was employed in this study. The reason we 
chose this mutant is that its mechanism of action is indis-
tinguishable from wild-type survivin, where it binds and 
organizes microtubular assembly during the interphase. 
Also, it has neither interference with the separation of chro-
mosomes nor with cell division mimicking the actions of 
wild-type survivin during mitosis.41 Therefore, we report here 
the proliferative potential of SurR9-C84A on differentiated 
neurons, and added to this our previous results also confirmed 
the neuroprotective activity of SurR9-C84A.14 Though vari-
ous mutant forms of survivin exist, such as survivin T34A, 
survivin C84A, survivin T34A-C84A,63 and survivin-D53A, 
none of them is reported to have the bifunctional activity 
exhibited by SurR9-C84A.14 Therefore, targeting survivin 
by the mutant SurR9-C84A seems to have great potential as 
a therapy for neuronal proliferation and neuroprotection. In 
order to determine the proliferative effects, SurR9-C84A-
loaded NPs were treated with differentiated SK-N-SH 
cells that behaved like neurons. Interestingly, they showed 
increased incorporation of BrdU (Figure 4F) specific to cell 
proliferation and also increased expression of survivin and 
proliferation markers PCNA and Ki67 (Figure 4, A–E). Dif-
ferentiated SK-N-SH cells showed reduced or no expression 
of survivin, due to their inability to divide, while treatment 
with SurR9-C84A enhanced their proliferative potential. 
This mechanism is explained by SurR9-C84A being able 
to interact with the microtubular assembly and initiate the 
spindle formation, which is similar to the actions of endog-
enous survivin (Figure 7).13,41
We report here for the first time a comparative effect of 
nanoformulated SurR9-C84A on undifferentiated (tumorous 
neuroblastoma) and differentiated SK-N-SH (neuronal) cells, 
where it showed a dual effect on these forms. These dual 
effects observed with SurR9-C84A were due to the differ-
ential expression of endogenous survivin levels. A cytotoxic 
effect was evident in high wild-type survivin-expressing 
undifferentiated cells, due to the displacement of endogenous 
survivin by SurR9-C84A and disturbed microtubular dynam-
ics. In contrast, a proliferative effect was reported for the 
differentiated cells, owing to their low endogenous survivin 
levels, where SurR9-C84A effects were indistinguishable 
from wild-type survivin. These effects were observed through 
the upregulation of Cas-3, Cyt-C, cyclin D1, annexin and PI+ 
cells in undifferentiated cells, while the reverse effects were 
noticed in differentiated cells.
Conclusion
We attempted to demonstrate the dual actions of SurR9-C84A, 
where it showed unique actions on undifferentiated (cytotoxic) 
and differentiated (proliferative) SK-N-SH cells. This drives 
the potential future application of SurR9-C84A for treating a 
variety of neurological disorders, and the beauty of this therapy 
would be the selective killing of brain tumor cells owing to 
the nature of high endogenous survivin expression sparing the 
neurons. Also, initiation of neuronal proliferation would be 
a tremendous application in culminating neurodegenerative 
diseases where neuronal loss is a classical hallmark. Further, 
future perspectives include the development of aptamer-
conjugated brain-targeted delivery of SurR9-C84A, which 
would enhance bioavailability and therapeutic output.
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